NEW YORK, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clever Leaves (the Company), a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that its Colombian operations have been named a Project of National and Strategic Interests (PINE) by the Government of Colombia. The PINE designation highlights the Colombian governments continued support of Clever Leaves work within the industry, as well as the importance of its economic contributions to Colombia and the growing medical cannabis industry. The PINE designation will offer Clever Leaves accelerated and simplified administrative processes as the Company continues to develop new products and services and bring them to market.
Clever Leaves has worked closely with the Colombian government since inception to commercialize and export high-quality Colombian cannabis, as well as finished and semi-finished medical cannabis products, with a focus on operational sustainability and high production standards. Clever Leaves has received multiple international quality certifications that have enabled it to increase its export capabilities from Colombia, including the first and only Good Manufacturing Practices (GMP) Certification by INVIMA to a cannabis company; Good Agricultural and Collecting Practices (GACP) Certification; and the only European Union Good Manufacturing Practices (EU GMP) Certification for a cannabis company in LATAM.
"The PINE designation is a reflection of our continued efforts to work in partnership with the Colombian government and recognition of the significant contributions to the countrys medical cannabis industry and broader economy. We pride ourselves on creating a business that not only generates a positive return on investment but demonstrates operational sustainability and positively impacts the community in which we operate, said Kyle Detwiler, CEO of Clever Leaves. We anticipate the PINE declaration to help streamline processes and coordination with government entities as we work to commercialize Colombian medical cannabis products and respond to evolving industry needs.
We appreciate the Colombian governments identification of Clever Leaves as a leader within the Colombian industry and their support to bring EU-GMP certified cannabis products to patients both domestically and internationally. With this additional government commitment supporting efficient and optimized processes and procedures, Clever Leaves continues to establish Colombia as an epicenter for medical cannabis production, while ensuring that the industry continues to create a significant economic impact on an international and regional level, said Andrés Fajardo, President of Clever Leaves.
For all business inquiries, please visit Clever Leaves direct to business sales platform, www.cleverleaves360.com, to set up an appointment with a Clever Leaves business consultant.
Clever Leaves was also recently in the news when they announced a potential business combination with Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA, SAMAW, and SAMAU) (SAMA) and disclosed the signing of a definitive agreement on July 27th. The transaction is expected to close in the fourth quarter of 2020 and the combined company is anticipated to trade on the NASDAQ under the symbol CLVR".
About Clever Leaves International Inc.
Clever Leaves is a multi-national cannabinoid company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabinoid business. With operations and investments in Canada, Colombia, Germany, Portugal, and the United States, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industrys leading global cannabinoid companies recognized for its principles, people, and performance while fostering a healthier global community.
Additional Information and Where to Find It
In connection with the Business Combination, Clever Leaves Holdings Inc. (Holdco) has filed a Registration Statement on Form S-4 (the Form S-4) with the SEC which includes a prospectus with respect to Holdcos securities to be issued in connection with the Business Combination and a proxy statement with respect to SAMAs stockholder meeting at which SAMAs stockholders will be asked to vote on the proposed Business Combination. SAMA, Clever Leaves and Holdco urge investors, stockholders and other interested persons to read the Form S-4, including the proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the Business Combination. The definitive proxy statement/prospectus will be mailed to stockholders of SAMA as of a record date to be established for voting on the Business Combination. SAMAs stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Schultze Special Purpose Acquisition Corp, 800 Westchester Avenue, Suite 632, Rye Brook, New York 10573; e-mail: sdu@samco.net. These documents, once available, can also be obtained, without charge, at the SECs web site (http://www.sec.gov).
Participants in Solicitation
SAMA, Clever Leaves, Holdco and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of SAMA stockholders in connection with the Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SAMAs stockholders in connection with the Business Combination is set forth in the preliminary proxy statement/prospectus contained in the Form S-4, and will also be included in the definitive proxy statement/prospectus for the Business Combination when available. Information concerning the interests of SAMAs and Clever Leaves participants in the solicitation, which may, in some cases, be different than those of SAMAs and Clever Leaves equity holders generally, is also set forth in the proxy statement/prospectus contained in the Form S-4, and will also be included in the definitive proxy statement/prospectus for the Business Combination when available.
Forward Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be identified by the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions). Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Factors that may cause such differences include, without limitation, SAMAs and Clever Leaves inability to complete the Business Combination; matters discovered by the parties as they complete their respective due diligence investigation of the other; the inability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by SAMA stockholders; the ability to meet NASDAQ's listing standards following the consummation of the Business Combination; costs related to the Business Combination; expectations with respect to future operating and financial performance and growth, including when Clever Leaves or Holdco will become cash flow positive; the timing of the completion of the Business Combination; Clever Leaves ability to execute its business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; global economic conditions; geopolitical events, natural disasters, acts of God and pandemics, including, but not limited to, the economic and operational disruptions and other effects of COVID-19; regulatory requirements and changes thereto; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC. Other factors include the possibility that the proposed transaction does not close, including due to the failure to receive required security holder approvals, the failure to obtain an extension of the business combination deadline if sought by SAMA or the failure to satisfy other closing conditions. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in the Form S-4, including the proxy statement/prospectus. All subsequent written and oral forward-looking statements concerning SAMA, Clever Leaves or Holdco, the transactions described herein or other matters and attributable to SAMA, Clever Leaves, Holdco or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of SAMA, Clever Leaves and Holdco expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Copyright © 2024 - Todos os direitos reservados para o Grupo Estado.
As notícias e cotações deste site possuem delay de 15 minutos.